Physician profile
Xiaoming Yang
NPI 1760785273
$1,833.44
in general payments reported to CMS, 2019-2025
15 companies · $31.36 in 2025
The $31.36 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $348 · 2022: $489 · 2023: $644 · 2024: $322 · 2025: $31.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $566.55 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $440.80 | 2021-2024 | Eliquis, Camzyos |
| Abbvie INC. | $162.80 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $161.07 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $83.22 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $67.26 | 2023 | Nuzyra |
| Gilead Sciences, INC. | $63.16 | 2021-2022 | |
| Pfizer INC. | $50.61 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $44.53 | 2021 | |
| Merck Sharp & Dohme LLC | $42.63 | 2023-2024 | Dificid, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.43 | 2022 | |
| Aimmune Therapeutics, INC. | $30.93 | 2024 | |
| Mallinckrodt Hospital Products INC. | $30.45 | 2024 | Terlivaz |
| Actelion Pharmaceuticals US, INC. | $26.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.02 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoming Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.